Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus
- 1 January 1992
- journal article
- research article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 15 (1) , 97-102
- https://doi.org/10.1016/0168-8227(92)90074-2
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humansDiabetes, 1990
- Islet amyloid polypeptide, a novel pancreatic peptide, is a circulating hormone secreted under glucose stimulationBiochemical and Biophysical Research Communications, 1990
- Failure of islet amyloid polypeptide to inhibit basal and glucose‐stimulated insulin secretion in model experiments in mice and ratsActa Physiologica Scandinavica, 1990
- Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogsDiabetologia, 1990
- Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in manDiabetologia, 1990
- Establishment of radioimmunoassay for human islet amyloid polypeptide and its tissue content and plasma concentrationBiochemical and Biophysical Research Communications, 1989
- Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic isletsDiabetologia, 1989
- Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic isletsBiochemical and Biophysical Research Communications, 1989
- Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitroNature, 1988
- Longitudinal studies on the development of diabetes in individual Macaca nigraDiabetologia, 1986